Author: Louis Navellier and the InvestorPlace Research Staff

It’s a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

It’s offering an opportunity of significant long-term growth potential with relatively low risk.

In light of rock-solid revenues and a growing user pool, it’s not hard to justify the stock’s fast-rising share price.

Now might be the time to think about adding it to your portfolio.